Second-line lurbinectedin as a new treatment option for small-cell lung cancer: Preliminary results in real-clinical practice.
lurbinectedin
safety profile
salvage chemotherapy
small cell lung cancer
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
revised:
24
04
2022
received:
10
03
2022
accepted:
25
04
2022
pubmed:
19
6
2022
medline:
5
8
2022
entrez:
18
6
2022
Statut:
ppublish
Résumé
Few strategies exist for treatment of patients with small-cell lung cancer (SCLC) extended-stage after failure of first-line platinum-based chemotherapy. Lurbinectedin is a novel RNA-polymerase-II inhibitor investigated as a second-line therapy for SCLC. However, its efficacy and safety profile in real clinical practice remain to be determined. To determine the efficacy and safety of lurbinectedin in real-life among patients with SCLC previously treated with first-line platinum-based chemotherapy. We retrospectively evaluated patients who received at least one dose of lurbinectedin (3.2 mg/m Thirteen patients were included. The median age was 60 years (range: 42-77), seven (54%) were females, nine (69%) having a performance status of 0-1. Lurbinectedin was given as second-line treatment before platinum rechallenge in four (31%) patients. After a mean follow-up of 4.1 months, the objective response rate (ORR) was 17%. The median time to treatment discontinuation (TTD) was 2.3 months (interquartile range [IQR], 1.2-3.6). The median progression-free survival (PFS) and overall survival (OS) were, respectively, 1.9 (IQR, 0.1.8) and 4.1 (IQR, 2.0-3.5) months. No significant difference regarding TTD, PFS or OS was found in the two groups according to treatment history or according to chemotherapy-free intervall (CMI) 〈1 or 〉1 month. The most common adverse events (AEs) were asthenia, nausea, and anemia in nine (70%) patients. Grade 3 AEs were reported, fatigue, vomiting, nausea, anorexia, and neutropenia. Lurbinectedin in real clinical practice could have had a lower efficacy than in phase II trial, but a better hematological and bioclinical tolerance than previously reported. Early relapse after platinum-based chemotherapy seems to have a lower response to lurbinectedin.
Identifiants
pubmed: 35715960
doi: 10.1111/1759-7714.14464
pmc: PMC9346176
doi:
Substances chimiques
Carbolines
0
Heterocyclic Compounds, 4 or More Rings
0
PM 01183
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2248-2252Informations de copyright
© 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Thorac Cancer. 2022 Aug;13(15):2248-2252
pubmed: 35715960
Sci Rep. 2015 Oct 21;5:15437
pubmed: 26486755
Clin Lung Cancer. 2015 Nov;16(6):e223-8
pubmed: 25983005
Lancet Oncol. 2020 May;21(5):645-654
pubmed: 32224306
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
Ann Oncol. 2013 Oct;24 Suppl 6:vi99-105
pubmed: 23813929
Lancet. 2019 Nov 23;394(10212):1929-1939
pubmed: 31590988